Skip to content
Peptide research

CJC-1295

Also known as Modified GRF(1-29) · Mod GRF
Category
Growth Hormone
Administration routes
Injectable
Regulatory status
Not FDA-approved

A synthetic growth hormone-releasing hormone analog, often built with a Drug Affinity Complex (DAC) that extends its half-life to days, marketed for body composition, sleep, recovery, and bone. It reliably raises growth hormone, but the clinical benefits remain speculative in humans. Safety is the gap: long-term data is thin, the long-acting form is hard to stop, and it can cause water retention and joint pain. Not an approved US drug and banned by WADA.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) — the natural signal your brain sends to the pituitary gland to produce growth hormone. It comes in two forms: CJC-1295 with DAC (Drug Affinity Complex), which binds to a blood protein called albumin giving it a 6-8 day half-life, and CJC-1295 without DAC (also called Modified GRF 1-29), which has a shorter ~30-minute half-life. Originally developed by ConjuChem Biotechnologies.

How it works in the body

Mimics growth hormone-releasing hormone (GHRH) by binding to GHRH receptors in your pituitary gland, signaling it to produce and release more growth hormone. With the DAC (Drug Affinity Complex) modification, it binds to albumin in your blood, extending its activity from minutes to days.

Research overview

CJC-1295 works by binding to GHRH receptors on the pituitary gland, triggering the natural signaling cascade that stimulates growth hormone production and release. A single injection of the DAC version can increase growth hormone levels 2-10 fold for 6 or more days, and raise IGF-1 (insulin-like growth factor 1) levels 1.5-3 fold for 9-11 days. Importantly, it preserves the body's natural pulsatile pattern of growth hormone release rather than producing a constant, unnatural elevation — a physiological finding that has not established greater clinical safety than direct growth hormone injections. The non-DAC version (Mod GRF 1-29) is often preferred in wellness protocols because its shorter duration allows for more precise dosing control. Clinical data comes primarily from the DAC version's development program, which demonstrated sustained GH and IGF-1 elevation in human subjects. However, full Phase 3 clinical trials were never completed, and ConjuChem discontinued development.

Who researches CJC-1295?

Commonly researched by

  • People exploring tissue repair and injury recovery

    Studied for effects on wound healing, tendon/ligament repair, or recovery from injury.

  • People exploring sleep quality improvement

    Researched for effects on sleep architecture, circadian rhythm, or sleep quality.

  • People researching bone health and density

    Studied for effects on bone mineralization, fracture healing, or osteoporosis.

Important considerations for

  • Those with Active cancer

    High

    Sustained GH elevation via GHRH mimicry may promote tumor growth.

  • Those with Pituitary tumors

    Absolute

    Directly stimulates pituitary GHRH receptors.

  • Those with Diabetic retinopathy

    High

    GH/IGF-1 axis activation can accelerate retinal damage.

  • Those who are pregnant or breastfeeding

    Absolute

    No safety data.

Safety & interactions

Do not use if

  • Pituitary tumors

    Absolute

    Directly stimulates pituitary GHRH receptors.

  • Active cancer

    High

    Sustained GH elevation via GHRH mimicry may promote tumor growth.

  • Diabetic retinopathy

    High

    GH/IGF-1 axis activation can accelerate retinal damage.

General cautions

  • Pregnancy

    Absolute

    No safety data.

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(6)

Rated by level of concern

  • One Phase II death was reported; coronary artery disease was considered the likely explanation, with drug causality unresolved.

    Low

    aidsmap (Jul 2006); ClinicalTrials.gov NCT00267527

  • Long-term safety data beyond a few months is lacking

    High

    PMID 16352683; program discontinued 2006

  • DAC version half-life 6-8 days cannot quickly discontinue if adverse reaction

    Moderate

    PMID 16352683 (half-life 5.8-8.1 days)

  • Water retention (hands, feet, face)

    Moderate

    GH/IGF-1 pharmacology (mechanism/class effect)

  • Potential GH-related side effects: joint pain, carpal tunnel, insulin resistance

    Moderate

    GH-excess pharmacology (mechanism/class effect)

  • WADA banned

    High

    WADA Prohibited List S2.2 (growth hormone-releasing factors)

Interaction summary(6)

Rated by direction with this peptide

  • Insulin and other antidiabetic agents (insulin, sulfonylureas, metformin)

    CautionModerate

    Sustained GH elevation induces insulin resistance and can raise blood glucose, blunting glycemic control and potentially requiring antidiabetic dose adjustment.

    GH/IGF-1 pharmacology; well-documented GH effect on glucose metabolism (acromegaly/GH-therapy data)

  • Glucocorticoids (corticosteroids)

    CautionModerate

    Glucocorticoids suppress the GH/IGF-1 axis and blunt the pituitary GH response to GHRH, so they can reduce CJC-1295 efficacy while also compounding hyperglycemia.

    Endocrine literature on glucocorticoid suppression of the GH axis (mechanism-based)

  • Somatostatin analogs (octreotide, lanreotide)

    CautionModerate

    Somatostatin directly inhibits pituitary GH release and would antagonize or negate the GH secretion driven by CJC-1295.

    GH physiology (somatostatin is the direct physiological brake on GH; mechanism-based)

  • GH secretagogues / ghrelin mimetics (Ipamorelin, GHRP-2/6, MK-677)

    SynergisticModerate

    Pairing a GHRH analog with a GHRP/ghrelin-mimetic produces supra-additive GH release via complementary mechanisms, which also amplifies GH-related side effects.

    GHRH+GHRP synergy literature (multiple human studies at class level; mechanism-based)

  • Recombinant growth hormone (somatropin)

    CautionTheoretical

    Co-administration risks additive GH/IGF-1 excess; exogenous GH also raises somatostatin tone via negative feedback, which could paradoxically blunt the GHRH-driven response. Not studied in combination.

    GH-axis negative feedback (mechanism-based; no combination trial)

  • Sex steroids (androgens / estrogens)

    NeutralTheoretical

    Relabeled from Synergistic to Neutral: the net effect is modulatory and mixed, not a unidirectional synergy or safety hazard. Sex-steroid priming (e.g., testosterone) augments GHRH-stimulated GH secretion, whereas oral estrogen LOWERS hepatic IGF-1 output (an opposing effect on the axis). This shifts response rather than adding risk.

    GH-axis endocrinology (mechanism-based)

Known risks(6)

  • One death during a Phase II trial; coronary artery disease was reported as the likely explanation, but drug causality was not conclusively excluded.

  • Long-term safety data beyond a few months is lacking

  • DAC version half-life 6-8 days — cannot quickly discontinue effects if adverse reaction

  • Water retention (hands, feet, face)

  • Potential for GH-related side effects: joint pain, carpal tunnel, insulin resistance

  • WADA banned

Drug interactions(3)

  • Ipamorelin

    Standard clinical combination. Different receptor pathways produce 3-5x GH release vs either alone.

  • GHRP-6

    Similar synergy to ipamorelin but with more side effects (hunger, cortisol)

  • Somatostatin analogs

    Would counteract GH-releasing effect

Research & benefits

Evidence base

Evidence Level
Phase 2 (Discontinued)
Total Studies
8
Human Studies
3

Foundational 2006 Teichman et al. RCT demonstrated dose-dependent GH/IGF-1 elevation. Ionescu 2006 confirmed preserved pulsatility. Development halted after Phase II death (attributed to pre-existing CAD). No further pharma-sponsored trials.

Researched for(7)

Rated by confidence in the evidence

  • Sustained GH elevation

    High

    Human RCT showed GH rising 2 to 10x for 6+ days per injection, accumulating with repeat dosing.

    PMID 16352683 (J Clin Endocrinol Metab 2006;91(3):799-805)

  • Preserved GH pulsatility

    Medium

    Human trial data indicate the natural GH pulse pattern is maintained, unlike exogenous GH.

    PMID 17018654 (J Clin Endocrinol Metab 2006;91(12):4792-7)

  • Improved body composition

    Speculative

    Preliminary, based on the GH/IGF-1 rise promoting lipolysis and lean mass; no completed outcome trial.

    Mechanistic extrapolation from GH/IGF-1 rise (PMID 16352683); lipodystrophy trial NCT00267527 halted 2006

  • Enhanced sleep quality

    Speculative

    Preliminary and mechanism-based; GHRH activity favors slow-wave sleep, with no CJC-1295 sleep studies.

    Mechanism only (no CJC-1295-specific data)

  • Accelerated recovery

    Speculative

    Preliminary and mechanism-based; elevated GH/IGF-1 supports tissue repair, without CJC-1295-specific data.

    Mechanism only (no CJC-1295-specific data)

  • Collagen/skin health

    Speculative

    Preliminary and mechanism-based; GH/IGF-1 signaling aids skin and connective tissue, no direct data.

    Mechanism only (no CJC-1295-specific data)

  • Bone density support

    Speculative

    Preliminary; IGF-1 rise is shown, but the bone benefit is mechanism-based extrapolation only.

    IGF-1 rise demonstrated (PMID 16352683); bone endpoint is mechanistic extrapolation

Benefits(8)

  • Sustained GH elevation

  • Preserved GH pulsatility

  • Improved body composition

  • Enhanced sleep quality

  • Accelerated recovery

  • Collagen/skin health

  • Bone density support

  • Synergy with Ipamorelin

Key studies(4)

  1. Teichman SL et al.

    J Clin Endocrinol Metab

    2006

    Dose-dependent GH 2-10x for 6+ days, IGF-1 1.5-3x for 9-11 days. Well tolerated.

  2. Ionescu M, Frohman LA

    J Clin Endocrinol Metab

    2006

    GH pulsatility preserved. Trough GH up 7.5x, total secretion up 46%.

  3. Alba M et al.

    Am J Physiol Endocrinol Metab

    2006

    Daily injections restored normal body weight and length in knockout mice

  4. Sackmann-Sala L et al.

    Growth Horm IGF Res

    2009

    Identified 5 serum biomarker changes linked to GH/IGF-1 activation

What research suggests over time

  • Weeks 2-4

    Teichman et al. JCEM 2006

    Sustained GH and IGF-1 elevation is detectable in serum; improved sleep was not established in the cited trial.

  • Months 2-3

    Practitioner-reported

    Improved recovery, body composition shifts, and lean tissue maintenance in practitioner cohorts.

  • Long-term

    Phase 1/2 trials

    Dose-dependent IGF-1 increases of up to 1.5-3× baseline sustained across multi-week dosing in published human studies.

Regulation & availability

Why researchers look at it

A single injection of the DAC version raises growth hormone levels 2-10 fold for six or more days and IGF-1 levels 1.5-3 fold for 9-11 days, preserving GH pulsatility, without demonstrated clinical safety superiority over synthetic GH. No Category 1 or other qualifying 503A bulk-compounding pathway has been identified for CJC-1295.

Estimated cost
No approved product and no verified reference price
FDA status
CJC-1295 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024. Development reached Phase II before discontinuation in 2006.
WADA status
Banned — classified as GH secretagogue under prohibited substances
Prescribability
CJC-1295 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024. WADA prohibits it.
Availability
Some clinics and telehealth platforms advertise CJC-1295. These listings do not establish lawful bulk compounding: it is unapproved, is not in Category 1, and remains on FDA's nominated-but-withdrawn safety table. No FDA-approved retail product exists. WADA prohibits it.

International status

  • EU

    Not approved

  • US

    CJC-1295 is not FDA-approved and is not eligible for compounding: it is not on FDA's list of bulk substances pharmacies may use, and an FDA advisory committee voted against adding it in December 2024.

  • Australia

    Schedule 4 via compounding with prescription

Regulatory timeline(3)

  1. 2006
    Phase I/II trials publishedTeichman and Ionescu studies in JCEM
  2. 2006
    Development haltedOne death in Phase II (attributed to pre-existing CAD). ConjuChem stopped development.
  3. 2023-09
    FDA Category 2Restricted from compounding

Sources & FAQs

Research sources(4)

Frequently asked questions(4)

DAC vs non-DAC?

DAC binds albumin for a 6-8 day half-life. Non-DAC (Mod GRF 1-29) has a half-life of about 30 minutes.

How long to see results?

Published trials establish GH and IGF-1 responses, but do not establish when sleep, energy or body-composition benefits occur.

Is it safe?

Well tolerated in trials at the doses studied. Reported effects include injection-site reactions, flushing and headache. FDA also identifies serious reactions involving increased heart rate and systemic vasodilation. One Phase II death attributed to pre-existing CAD. Long-term data lacking.

Legal in US 2026?

A prescription does not establish lawful compounding. CJC-1295 is unapproved and has no identified qualifying 503A bulk-compounding pathway. Some telehealth platforms advertise it. WADA prohibits it.